Indication: Multiple Sclerosis (MS)

An Open-Label, Parallel-Group Study To Evaluate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamic Effects Of Ocrelizumab In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis

Sub-indication: Multiple Sclerosis (MS)

Drug Study

Principal Investigator: Michael Sweeney, M.D.
Norton Children's Neurology, affiliated with the UofL School of Medicine

Sponsor: F. Hoffmann-LaRoche Ltd.

Search our entire site.